Preliminary Recommendation on Dolutegravir (DTG)
Document link: MEDICINES RECOMMENDED FOR INCLUSION IN THE PHILIPPINE NATIONAL FORMULARY (PNF) (Proponents may submit appeals to hta@doh.gov.ph until 10 September 2021.) Document Preview:
Tenofovir/Lamivudine/Dolutegravir (TLD) for Treatment-Naive and Treatment-Experienced Adolescents and Adults Living with HIV
Date of publication: August 24, 2021 Approved by the Secretary of Health: September 01, 2021 Evidence Summary: Tenofovir/Lamivudine/Dolutegravir for treatment-naive and treatment-experienced adolescents and adults living with HIV Advisory on non-inclusion in PNF: https://bit.ly/PR_TLD HTAC Recommendation Review: